Skip to main content

Site notifications

SANDRENA Orion Pharma (AUS) Pty Limited

Product name
SANDRENA
Accepted date
Oct-2025
Active ingredients
estradiol hemihydrate
Proposed indication
Sandrena (estradiol) is proposed for the prevention of bone loss (osteoporosis) in women who have gone through menopause and are at high risk of breaking bones. It is intended for those who cannot use, or do not tolerate, other approved medicines for preventing osteoporosis.
Application type
C (new indication)
Publication date
Oct-2025